Abstract
The prostate-specific membrane antigen (PSMA) is a great target for prostate cancer in the current. The MH-PC-AB-56, a molecule with PSMA-targeted activity and with an albumin-binding motif, was radiolabeled with indium as a diagnostic agent and with lutetium with a therapeutic agent, respectively. We evaluated the molecule's theranostic application with 111In and 177Lu in NanoSPECT/CT imaging. Methods: The radiolabeled peptide, 111In/177Lu-MH-PC-AB-56, was performed with sodium acetate buffer and heating with 15 min or 30 min at 95℃. The radiochemical purity was analyzed by TLC and HPLC. The PSMA-expressed tumor cell LNCaP was implanted right front leg at BALB/c nude mice. NanoSPECT/CT image was performed at 1 h, 4 h, 24 h, 48 h, 72 h, and 96 h after injection of 111In-MH-PC-AB-56 or 177Lu-MH-PC-AB-56. Results: The radiochemical purity of 111In-MH-PC-AB-56 or 177Lu-MH-PC-AB-56 was 99.09 ± 0.38% and 98.87 ± 0.73% by radio-HPLC analysis, respectively. The in vitro labeling stability of both radiolabeled peptide was 97.0% ± 0.8% and 94.5% ± 2.5% at 4 h in normal saline by radio-HPLC analysis, respectively. The highest uptake of 111In-MH-PC-AB-56 in the tumor appeared at 24 h (43.78 ± 6.55%ID/g), and the uptake in the tumor was a decline after 24 h. During 1 h to 4 h, the kidney and muscle had the highest accumulation of 111In-MH-PC-AB-56 with 37.62 ± 3.69%ID/g to 39.66 ± 7.59%ID/g and 6.58 ± 0.59%ID/g to 6.70 ± 0.45%ID/g, respectively. The highest uptake of 177Lu-MH-PC-AB-56 in the tumor appeared at 24 h (22.08 ± 6.63%ID/g) and retained until 96 h (23.41 ± 5.18%ID/g). During 1 h to 4 h, the kidney had the highest accumulation of 177Lu-MH-PC-AB-56 with 40.35 ± 4.89%ID/g to 42.63 ± 20.14%ID/g. Conclusion: Our results indicated that both 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56 highly accumulated at the tumor lesion, and both 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56 were similar distribution in the liver and kidney with positive correlation (r = 0.960 and 0.979) by NanoSPECT/CT imaging.
Access provided by Autonomous University of Puebla. Download conference paper PDF
Similar content being viewed by others
Keywords
1 Introduction
Prostate-specific membrane antigen (PSMA) is expressed higher in prostate tumors and metastases than most normal tissue. This pathological expression pattern leads it to be a target for endoradiotherapy of prostate cancer [1, 2]. The albumin binding structure has modified to the target molecule lets the kinetic of the molecule in the blood to change. In addition, extending the circulating-time of drugs in the body is a method to enhance the efficacy of drugs [3].
In this study, we have developed a novel long-circulation PSMA-targeted molecule, MH-PC-AB-56, which PSMA binding motif (PSMA-617 structure without DOTA) covalently linked with albumin binder (4-p-tolylbutyric acid), and conjugated DOTA chelator, and labeled with radionuclide 111In or 177Lu. We investigated the tumor binding affinity and biodistribution by molecular imaging of radiolabeled MH-PC-AB-56 peptide. The major objective of this study was to evaluate the potential advantage of MH-PC-AB-56 in the theranostic application by NanoSPECT image.
2 Materials and Methods
-
A.
Cell culture and tumor-bearing mice
The PSMA positive prostate cancer cell line, LNCaP, was obtained from Bioresource Collection and Research Center. Cells were grown in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin in a humidified incubator at 37 ℃ under 5% CO2. Six-week-old male BALB/c nude mice were obtained from BioLASCO Taiwan Co., Ltd. Mice were housed in a 12 h light cycle at 22 ℃, with food and water provided ad libitum. Cells (1 × 107) was implanted right front leg of BALB/c nude mice for LNCaP tumor xenografts. The mice underwent NanoSPECT/CT study when the tumor volume reached approximately 200–600 mm3. The animal experimental protocols were approved by INER Institutional Animal Care and Use Committee.
-
B.
Radiolabeling with indium-111 and lutetium-177
Indium (111In) chloride in 0.01 N HCl was generated from INER (Taoyuan, Taiwan). Lutetium (177Lu) chloride in 0.04 N HCl purchased from ITM Medical Isotopes GmbH (Garching/Munich, Germany). The peptide (MH-PC-AB-56 and PSMA-617) purchased from Ontores Biotechnologies Co., Ltd. (Zhejiang China).
For 111In-MH-PC-AB-56 labeling, the 13.9 nmole peptide (in DMSO) was incubation with 0.23–0.26 GBq 111InCl3 in 1 M sodium acetate solution (pH 6.0) at 95℃ for 15 min. The radiochemical efficiency analyzed by thin-layer chromatography (TLC) with 10% methanol and high-performance liquid chromatography (HPLC). For 177Lu-MH-PC-AB-56 labeling, the 13.9 nmole peptide (in DMSO) was incubation with 0.47–0.51 GBq 177LuCl3 in 0.4 M sodium acetate solution (pH 5.0) at 95℃ for 30 min. The radiochemical efficiency analyzed by TLC with 0.1 M citric acid and HPLC. For 177Lu-PSMA-617 labeling, the 19.2 nmole peptide (in water) was incubation with 0.47–0.51 GBq 177LuCl3 in 0.4 M sodium acetate solution (pH 5.0) at 95℃ for 30 min. The radiochemical efficiency analyzed by TLC with 0.1 M citric acid and HPLC. The specific activity for 111In-MH-PC-AB-56, 177Lu-MH-PC-AB-56 and 177Lu-PSMA-617 in the range of 16.5–18.7 GBq/µmole, 33.8–36.7 GBq/µmole and 24.5–26.6 GBq/µmole, respectively.
The radiolabeled peptides were measured using a radioactive scanner (AR-2000 radio-TLC Imaging Scanner, Bioscan, France) and radio-HPLC with UV detector (280 nm) and radio detector. The column was waters T3 C18 column (3.5 µm, 80 Å, 4.6 × 250 mm). The flow rate was 0.8 mL/min with the gradient mobile phase going from 80% A buffer (0.1% TFA in water) and 20% B buffer (0.1% TFA in acetonitrile) to 90% B buffer within 10 min for 111In-MH-PC-AB-56. The flow rate was 1.0 mL/min with the gradient mobile phase going from 95% A buffer (0.1% TFA in water) and 5% B buffer (0.1% TFA in acetonitrile) to 95% B buffer within 10 min for 177Lu-MH-PC-AB-56. The flow rate was 1.0 mL/min with the gradient mobile phase going from 80% A buffer (0.1% TFA in water) and 20% B buffer (0.1% TFA in acetonitrile) to 60% B buffer within 10 min for 177Lu-PSMA-617.
-
C.
In vitro stability study
The stability of 111In-MH-PC-AB-56 evaluated by incubation with normal saline (volume ratio 1:1) at room temperature or human serum (volume ratio 1:19) at 37℃ [4]. The radiochemical purity determined by TLC and HPLC analysis at desired times (0, 1, 4, 24, 48, 72 and 96 h). The serum sample was prepared with acetonitrile/water solution and centrifuged at 13,000 rpm 2 min, then analyzed the supernatant by HPLC.
The stability of 177Lu-MH-PC-AB-56 evaluated by incubation with normal saline (volume ratio 1:1) at room temperature. The radiochemical purity determined by HPLC analysis at desired times (0, 1, 2, 3, 4, 5, 6, 7, 8 and 24 h).
-
D.
NanoSPECT/CT imaging
The procedure for NanoSPECT/CT imaging has been described, previously [5]. NanoSPECT and X-ray images were acquired using a NanoSPECT/CT plus scanner system (Mediso Medical Imaging Systems; Budapest, Hungary). The mice was anesthetized with 1–2% isoflurane during the imaging acquisition. NanoSPECT imaging was acquired using nine multipinholes gamma-detectors and high-resolution collimators. The energy window was set at 171 and 245 keV ± 10%, the image size was set at 256 ± 256, and the field of view of 60 mm × 100 mm. Each mouse was tail-vein injected with 19.4–20.7 MBq of radiolabeled peptide and scanned for 1 h, 4 h, 24 h, 48 h, 72 h and 96 h.
For calculating uptake value at an interesting organ of 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56, the images of SPECT reconstructed by HiSPECT NG software (Scivis GmbH, Germany) and fused with CT datasets using InVivoScope software (Bioscan Inc.). Then, all data processed by PMOD Version 3.3 (PMOD Technologies Ltd., Zurich, Switzerland). Volumes of Interest (VOIs) drawn encompassing the tumor and reference source on the corresponding CT images. The VOIs transferred to SPECT images, and the count values of the tumor and reference source derived. The radioactivity of reference sources were 0.8 MBq 111In and 1.3 MBq 177Lu.
-
E.
Statistics
Results presented as mean and standard deviation (Mean ± SD). The distribution correlation between 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56 was analyzed by Pearson correlation coefficient (r) using IBM® SPSS® Statistics software version 19 [5].
3 Results
-
A.
Radiolabeling efficiency of MH-PC-AB-56
The labeling efficiency of 111In-MH-PC-AB-56 was 98.27 ± 1.29% and 99.09 ± 0.38% by TLC and HPLC analysis, respectively. In TLC, free 111In was at origin front (Rf. approximately 0.000) and 111In-MH-PC-AB-56 was at solvent front (Rf. approximately 0.917) with 10% methanol as running buffer. The retention time of 111In-MH-PC-AB-56 was 8.569 ± 0.010 min in radio detector by HPLC.
The labeling efficiency of 177Lu-MH-PC-AB-56 was over 99.99% and 98.87 ± 0.73% by TLC and HPLC analysis, respectively. In TLC, free 177Lu was at origin front (Rf. approximately 1.023) and 177Lu-MH-PC-AB-56 was at solvent front (Rf. approximately 0.015) with 0.1 M citric acid as running buffer. The retention time of 177Lu-MH-PC-AB-56 was 8.587 ± 0.262 min in radio detector by HPLC.
The labeling efficiency of 177Lu-PSMA-617 was over 99.99% and 98.68% by TLC and HPLC analysis, respectively. In TLC, free 177Lu was at solvent front (Rf. approximately 1.045) and 177Lu-PSMA-617 had Rf. 0.435 with 0.1 M citric acid as eluted buffer. The retention time of 177Lu-PSMA-617 was 8.247 min in radio detector HPLC.
-
B.
In vitro stability study of 111In-MH-PC-AB-56
The radio-purity of 111In-MH-PC-AB-56 was greater than 95% within 96 h incubation in normal saline or human serum (Table 1).
-
C.
In vitro stability of 177Lu-MH-PC-AB-56 in normal saline
The stability of 177Lu-MH-PC-AB-56 in normal saline was greater than 95% within 8 h incubation by HPLC (Table 2).
-
D.
NanoSPECT/CT imaging
The images showed that both radiolabeled 111In/177Lu-MH-PC-AB-56 and 177Lu-PSMA-617 were excreted mainly via the renal pathway with higher renal retention especially at early time points 1 h and 4 h injection. Higher and sustained tumor uptake was observed for radiolabeled MH-PC-AB-56 up to 96 h by imaging (Fig. 1).
The accumulated activity of radiolabeled 111In/177Lu-MH-PC-AB-56 in the tumor at time points was calculated from the images created by drawing the Volume of Interest (VOI) using the standard source as a point of reference. The image semi-quantitative analysis of 111In-MH-PC-AB-56 in the tumor at 1 h, 4 h, 24 h, 48 h, 72 h and 96 h after injection was 19.79 ± 2.27, 27.32 ± 2.85, 43.79 ± 6.55, 35.48 ± 4.53, 27.77 ± 4.30, and 25.06 ± 3.77%ID/g, respectively (Table 3). The image semi-quantitative analysis of 177Lu-MH-PC-AB-56 in the tumor at 1 h, 4 h, 24 h, 48 h, 72 h and 96 h after injection was 12.91 ± 2.69, 17.98 ± 3.20, 22.08 ± 6.63, 21.56 ± 4.90, 22.80 ± 5.29, and 23.41 ± 5.18%ID/g, respectively (Table 3). The trend of tumor uptake of 111In-MH-PC-AB-56 is similar to 177Lu-MH-PC-AB-56 before 24 h injection. After 24 h injection, the tumor uptake of 111In-MH-PC-AB-56 was slightly declining, but the tumor uptake of 177Lu-MH-PC-AB-56 sustained last for at least 96 h.
Pearson correlation analysis of tumor uptake of 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56 by semi-quantification image analysis was moderated degree (r = 0.576). There was a high correlation of liver, kidney, and muscle of 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56 with value 0.960 (Table 4), 0.960 (Table 5), and 0.940 (Table 6), respectively.
4 Conclusions and Discussion
Many albumin binders (truncated Evan’s blue, 4-(phenyl)butyric acid, 4-(p-bromophenyl)butyric acid, 4-(p-iodophenyl)butyric acid, 4-(p-chlorophenyl)butyric acid, 4-(p-fluorophenyl)butyric acid, 4-(p-methyl phenyl)butyric acid, and 4-(p-methoxyphenyl)butyric acid) had been used in modified PSMA-617 to enhance the circulating-time of PSMA-targeted drug to drawdown the accumulation of drug at kidney and improved tumor uptake [6]. We explored a novel linker lysine and 6-aminohexanoic acid not like PSMA-ALB-56 [7] only lysine or RPS [8] used PEG before. The structure is not only longer of length than lysine but also more lipophilic than PEG. In vitro stability study showed, the radiochemical purity of 177Lu-MH-PC-AB-56 maintain to over 90% last at least 8 h without ascorbic acid addition. The SPECT image show that MH-PC-AB-56 labeled with dual-nuclide have a similar trend of metabolism or elimination organ, and demonstrated 177Lu-MH-PC-AB-56 could improve tumor uptake than 177Lu-PSMA-617. These results let us know the tumor accumulated ability and elimination route of radiolabeled MH-PC-AB-56. These results indicated the 111In/177Lu-MH-PC-AB-56 owned the theranostic potency for diagnosis and therapy. The therapeutic efficacy, pharmacokinetics, and biodistribution would be further studied in the near future.
References
Rahbar et al (2018) Mol Imaging 17:1–9. https://doi.org/10.1177/1536012118776068
Langbein et al (2019) J Nucl Med 60:13S-19S. https://doi.org/10.2967/jnumed.118.220566
Kuo et al (2018) Mol Pharmaceutics 15:5183–5191. https://doi.org/10.1021/acs.molpharmaceut.8b00720
Lo et al (2020) Appl Radiat Isot 161:109126. https://doi.org/10.1016/j.apradiso.2020.109162
Chang et al (2007) Anticancer Res 27:2217–2226
Kuo et al (2020). J Nucl Med. https://doi.org/10.2967/jnumed.120.250738
Umbricht et al (2018) Mol Pharm 15:2297–2306. https://doi.org/10.1021/acs.molpharmaceut.8b00152
Kelly et al (2019) J Nucl Med 65:656–663. https://doi.org/10.2967/jnumed.118.221150
Acknowledgements
We thanked the support from the Ministry of Economic Affairs, ROC with grant number 108-EC-17-A-22-1587.
Funding
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Li, MH. et al. (2022). Evaluation of Radiolabeling PSMA-Targeted Long Circulating Peptide as a Theranostic Agent in Human Prostate Tumor-Bearing Mice. In: Lin, KP., Liu, RS., Yang, BH. (eds) Future Trends and Challenges of Molecular Imaging and AI Innovation. FASMI 2020. Springer Proceedings in Physics, vol 272. Springer, Cham. https://doi.org/10.1007/978-3-030-92786-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-92786-8_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-92785-1
Online ISBN: 978-3-030-92786-8
eBook Packages: Physics and AstronomyPhysics and Astronomy (R0)